Veolity

MeVis Medical Solutions AG

Veolity LungRead is a reading solution dedicated to lung screening programs as well as incidental pulmonary nodule management. It combines lung CAD of solid, non-solid, part-solid, and calcified pulmonary nodules, automatic nodule type classification, volumetric nodule quantification, interactive temporal comparison and nodule tracking, and creates a guideline-compliant report. Veolity supports reporting according to Lung-RADS, BTS Guidelines, BC Lung Screening Protocol incl. Nodule Malignancy Risk Estimation (according to the Brock model).
Veolity’s AI automatically marks regions that are suggestive of pulmonary nodules to identify regions that demand further analysis and may have been previously overlooked by the human eye.
Product specifications Information source: Vendor
Last updated: Nov. 26, 2023
General
Product name Veolity
Company MeVis Medical Solutions AG
Subspeciality Chest
Modality CT
Disease targeted Lung Cancer
Key-features Nodule detection, segmentation and quantification, temporal registration and nodule comparison, report generation according to guidelines
Suggested use Before: flagging acute findings
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion
Data characteristics
Population Chest CTs on an asymptomatic population
Input 3D chest CT
Input format DICOM
Output CAD report, CAD overlay, radiology report
Output format DICOM SR, DICOM SC, DICOM GSPS, XML, PDF, TXT
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis Automatically, right after the image acquisition
Processing time
Certification
CE
Certified, Class IIa , MDR
FDA
 510(k) cleared, Class II
Market presence
On market since 03-2015
Distribution channels Blackford
Countries present (clinical, non-research use) 25+ (including Europe, USA, Canada, Australia, Republik of Korea, Hong Kong, New Zealand)
Paying clinical customers (institutes) 500+
Research/test users (institutes) Veolity is used in several clinical trials world-wide
Pricing
Pricing model
Based on
Evidence
Peer reviewed papers on performance

  • Assisted versus Manual Interpretation of Low-Dose CT Scans for Lung Cancer Screening: Impact on Lung-RADS Agreement (read)
Non-peer reviewed papers on performance
Other relevant papers